Cargando…

Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy

Chronic thromboembolic pulmonary hypertension (CTEPH) is classified as group-4 pulmonary hypertension caused by organized thrombi in pulmonary arteries and vasculopathy in nonoccluded areas leading to right heart failure and death. In addition to chronic anticoagulation therapy, each patient with CT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donaldson, Sahai, Ogunti, Richard, Kibreab, Angesom, Mehari, Alem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457580/ https://www.ncbi.nlm.nih.gov/pubmed/32904692 http://dx.doi.org/10.2147/CE.S172791

Ejemplares similares

Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series
por: Weir, Nargues A., et al.
Publicado: (2018)

Correction to: Clinical Characteristics and Predictors of Mortality in Minority Patients Hospitalized with COVID-19 Infection
por: Muhammad, Rizwan, et al.
Publicado: (2022)

Clinical Characteristics and Predictors of Mortality in Minority Patients Hospitalized with COVID-19 Infection
por: Muhammad, Rizwan, et al.
Publicado: (2021)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension
por: van Thor, M.C.J., et al.
Publicado: (2019)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension
por: Wiedenroth, Christoph B., et al.
Publicado: (2018)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice
por: Michaličková, Danica, et al.
Publicado: (2020)

Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis
por: Ying, Miaofa, et al.
Publicado: (2021)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center
por: Sulica, Roxana, et al.
Publicado: (2015)

Hypercalcemic pancreatitis a rare presentation of sarcoidosis: A case report
por: Gebreselassie, Agazi, et al.
Publicado: (2018)

Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension
por: Kenny, Marianne, et al.
Publicado: (2020)

Increased Arterial Stiffness in Chronic Thromboembolic Pulmonary Hypertension Was Improved with Riociguat and Balloon Pulmonary Angioplasty: A Case Report
por: Sato, Shuji, et al.
Publicado: (2021)

Real-world experience with riociguat as potential bridging therapy in patients with chronic thromboembolic pulmonary hypertension: a case series
por: Balasubramanian, Vijay P., et al.
Publicado: (2020)

Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta‐analysis
por: Wang, Wuwan, et al.
Publicado: (2019)

Combination of rescue balloon pulmonary angioplasty and riociguat therapy for chronic thromboembolic pulmonary hypertension with nonsustained polymorphic ventricular tachycardia: A case report
por: Fukuda, Yoshitake, et al.
Publicado: (2023)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Riociguat: Something new in pulmonary hypertension therapeutics?
por: Shanmugam, Elangovan, et al.
Publicado: (2015)

Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study
por: Kawakami, Takashi, et al.
Publicado: (2020)

Riociguat inhibits ultra‐large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients
por: Jujo Sanada, Takayuki, et al.
Publicado: (2022)

Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat
por: Smith, Zachary R, et al.
Publicado: (2016)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial
por: Zhao, Qin-Hua, et al.
Publicado: (2021)

Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice: interim data from post-marketing surveillance in Japan
por: Tanabe, Nobuhiro, et al.
Publicado: (2020)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
por: Wang, Chen, et al.
Publicado: (2016)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
por: García Aguilar, Humberto, et al.
Publicado: (2022)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
por: Lian, Tian-Yu, et al.
Publicado: (2017)

Trends in Pulmonary Hypertension Mortality and Morbidity
por: Mehari, Alem, et al.
Publicado: (2014)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
por: Mihalek, Andrew D, et al.
Publicado: (2022)

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling
por: Taran, Irina N., et al.
Publicado: (2018)

Chronic Thromboembolic Pulmonary Hypertension
por: Wittine, Lara M., et al.
Publicado: (2010)

Chronic thromboembolic pulmonary hypertension
por: Schölzel, B. E., et al.
Publicado: (2014)

Chronic thromboembolic pulmonary hypertension
por: Correale, Michele, et al.
Publicado: (2015)

Chronic thromboembolic pulmonary hypertension
por: Kim, Nick H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fsb5r1ths8rbc1karajj9of7s3